🌿 THE AFTER PROFILE
Androgen deprivation therapy suppresses testosterone to castrate levels — which is the point. The side effects — bone loss, muscle wasting, metabolic changes, fatigue, mood shifts — are real and well-documented. They are also partially manageable with targeted nutritional support that does not conflict with ADT goals.
The After stack is built around one constraint: zero testosterone-stimulating compounds. Every ingredient is selected for bone, metabolic, energy, and immune support — not androgen signaling. Oncologist coordination is required.
Build my protocol — freeTHE MECHANISM
“Men with prostate cancer receiving LHRH agonist therapy lose 2–3% bone mineral density per year — with a corresponding increase in fracture risk that compounds with treatment duration. Calcium and vitamin D supplementation are standard of care recommendations alongside ADT.”
Smith MR et al., New England Journal of Medicine (2001); Higano CS, Urology (2003) — review of ADT musculoskeletal effects
ADT-induced metabolic syndrome — increased visceral fat, insulin resistance, dyslipidemia — raises cardiovascular risk independent of cancer outcome. Alibhai SMH et al. showed ADT increases risk of diabetes and cardiovascular events, making metabolic management an essential part of survivorship care.
THE AFTER STACK
Not included — and never will be: Tongkat Ali, Fadogia agrestis, DHEA, Tribulus, Fenugreek, or high-dose boron. These stimulate androgen signaling and are contraindicated on ADT.
Bone density loss on ADT is rapid — men lose 2–3% annual bone mineral density within the first year of ADT. Vitamin D3 is essential for calcium absorption and bone remodeling. Higano CS et al. confirmed bone loss as a primary ADT side effect requiring active management. AM delivery with food for fat-soluble absorption.
Calcium citrate absorbs without requiring stomach acid — important for men on proton pump inhibitors, which are more common in this population. Bone density maintenance requires adequate calcium alongside vitamin D3. PM dosing avoids interference with iron or zinc absorption and spreads the daily calcium load.
ADT-induced mood changes (depression, emotional blunting) have a neuroinflammatory component that omega-3 addresses directly. EPA reduces inflammatory cytokines; DHA maintains prefrontal cortex membrane integrity. Alibhai SMH showed ADT-induced metabolic syndrome affects cardiovascular risk — omega-3 reduces TG and CRP.
Muscle cramping, sleep disruption, and fatigue — common ADT side effects — all have magnesium deficiency components. Lower dose than other profiles (300mg vs. 400mg) because calcium supplementation is already in the stack; calcium and magnesium compete for absorption when taken together. PM timing supports sleep architecture.
ADT-related fatigue is partly mitochondrial in origin — reduced androgen signaling impairs mitochondrial biogenesis. CoQ10 is the primary electron carrier in ATP production and is the most direct energy-chain intervention. AM dosing with a fat-containing meal for lipid-soluble absorption.
Immune function support at a non-testosterone-stimulating dose. ADT suppresses immune signaling alongside androgen signaling — zinc maintains T-cell function and mucosal immunity without meaningfully stimulating testosterone production at 15mg. Higher doses (30mg+) may mildly stimulate LH; this dose does not.
REQUIRED: ONCOLOGIST APPROVAL
All supplements require approval from your oncologist and urologist before starting. Some antioxidants interact with radiation therapy. This stack is designed for stable ADT maintenance — not during active treatment changes, radiation, or systemic chemotherapy. Bring this ingredient list to your next appointment.
“My oncologist actually helped me refine this stack — she confirmed the vitamin D and calcium were exactly what she'd recommend anyway. The After gave me a framework to have that conversation. Six months on ADT and my bone scan was stable.”
Paul H., 63
THE AFTER PROFILE
COMMON QUESTIONS
FOUNDING MEMBERS
$39/mo Essential or $69/mo Full Protocol — price locked forever.